JAZZ logo

Jazz Pharmaceuticals (JAZZ) Company Overview

Profile

Full Name:

Jazz Pharmaceuticals plc

Sector:

Healthcare

Industry:

Biotechnology

Country:

Ireland

IPO:

June 1, 2007

Indexes:

Not included

Description:

Jazz Pharmaceuticals is a global biopharmaceutical company that develops and sells medicines for serious health conditions. They focus on areas like sleep disorders, epilepsy, and cancer. Their goal is to improve patients' lives through innovative treatments and research.

Events Calendar

Earnings

Next earnings date:

May 1, 2025

Recent quarterly earnings:

Feb 25, 2025

Recent annual earnings:

Feb 25, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 27, 25 Barclays
Overweight
Feb 26, 25 RBC Capital
Outperform
Feb 26, 25 Piper Sandler
Overweight
Feb 26, 25 Needham
Buy
Feb 26, 25 JP Morgan
Overweight
Feb 26, 25 Cantor Fitzgerald
Neutral
Feb 13, 25 Wells Fargo
Overweight
Dec 12, 24 RBC Capital
Outperform
Dec 12, 24 Piper Sandler
Overweight
Dec 12, 24 Needham
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Jazz Pharmaceuticals?
  • Does Jazz Pharmaceuticals pay dividends?
  • What sector is Jazz Pharmaceuticals in?
  • What industry is Jazz Pharmaceuticals in?
  • What country is Jazz Pharmaceuticals based in?
  • When did Jazz Pharmaceuticals go public?
  • Is Jazz Pharmaceuticals in the S&P 500?
  • Is Jazz Pharmaceuticals in the NASDAQ 100?
  • Is Jazz Pharmaceuticals in the Dow Jones?
  • When was Jazz Pharmaceuticals's last earnings report?
  • When does Jazz Pharmaceuticals report earnings?
  • Should I buy Jazz Pharmaceuticals stock now?

What is the ticker symbol for Jazz Pharmaceuticals?

The ticker symbol for Jazz Pharmaceuticals is NASDAQ:JAZZ

Does Jazz Pharmaceuticals pay dividends?

No, Jazz Pharmaceuticals does not pay dividends

What sector is Jazz Pharmaceuticals in?

Jazz Pharmaceuticals is in the Healthcare sector

What industry is Jazz Pharmaceuticals in?

Jazz Pharmaceuticals is in the Biotechnology industry

What country is Jazz Pharmaceuticals based in?

Jazz Pharmaceuticals is headquartered in Ireland

When did Jazz Pharmaceuticals go public?

Jazz Pharmaceuticals's initial public offering (IPO) was on June 1, 2007

Is Jazz Pharmaceuticals in the S&P 500?

No, Jazz Pharmaceuticals is not included in the S&P 500 index

Is Jazz Pharmaceuticals in the NASDAQ 100?

No, Jazz Pharmaceuticals is not included in the NASDAQ 100 index

Is Jazz Pharmaceuticals in the Dow Jones?

No, Jazz Pharmaceuticals is not included in the Dow Jones index

When was Jazz Pharmaceuticals's last earnings report?

Jazz Pharmaceuticals's most recent earnings report was on Feb 25, 2025

When does Jazz Pharmaceuticals report earnings?

The next expected earnings date for Jazz Pharmaceuticals is May 1, 2025

Should I buy Jazz Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions